Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.

Shuo YangXiaoqin TangLong WangChengyang NiYuesong WuLing ZhouYueying ZengChunling ZhaoAn-Guo WuQiaozhi WangXiyan XuYiwei WangRong ChenXiao ZhangLile ZouXinwu HuangJian-Ming Wu

Published in: International journal of molecular sciences (2022)

Ruxolitinib was first identified to facilitate MK differentiation and thrombocytopoiesis, which may alleviate RIT. The potential mechanism of ruxolitinib was to promote MK differentiation via activating the Rac1/cdc42/JNK pathway through binding to TLR2.

Keyphrases

signaling pathway
toll like receptor
inflammatory response
cell death
immune response
induced apoptosis
cell cycle
cell migration
nuclear factor
cancer therapy
genome wide
gene expression
endoplasmic reticulum stress
dna methylation
climate change